Premium
CD33‐Targeted Therapies: Beating the Disease or Beaten to Death?
Author(s) -
Maakaron Joseph E.,
Rogosheske John,
Long Meixiao,
Bachanova Veronika,
Mims Alice S.
Publication year - 2021
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.1730
Subject(s) - gemtuzumab ozogamicin , cd33 , myeloid leukemia , antibody drug conjugate , medicine , cancer research , targeted therapy , immunoconjugate , monoclonal antibody , drug , myeloid , pharmacology , progenitor cell , targeted drug delivery , immunology , stem cell , antibody , biology , cancer , cd34 , microbiology and biotechnology
Abstract CD33 is a transmembrane protein that is found on cells of myeloid lineage. It is also intensely expressed on acute myeloid leukemia (AML) progenitor cells but not on normal stem cells. It internalizes on binding and dimerization, making it a specific and ideal target for AML therapeutics and drug delivery. Several targeted therapies have been tested and many are still currently in development. Gemtuzumab ozogamicin was the first and only CD33‐directed antibody‐drug conjugate to be US Food and Drug Administration approved for AML. Other targeted agents have not achieved such success. Promising new strategies include cellular therapy mechanisms and linker molecules. This is an exciting target that requires a considerable amount of precision to yield clinical benefit.